Citadel Advisors’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Citadel Advisors’s Portfolio TBIO Stock Details TBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-42,000	Closed	-$1.16M	–	15257
2021 Q2	$1.16M	Sell	42,000 -28,900	-41%	-$568K	﹤0.01%	7977
2021 Q1	$1.17M	Sell	70,900 -3,500	-5%	-$79.7K	﹤0.01%	7712
2020 Q4	$1.37M	Buy	74,400 +28,700	+63%	+$514K	﹤0.01%	6122
2020 Q3	$622K	Sell	45,700 -35,900	-44%	-$553K	﹤0.01%	6897
2020 Q2	$1.46M	Buy	+81,600	New	+$1.23M	﹤0.01%	5119

Citadel Advisors's TBIO Position: Q2 2021 in Review

Citadel Advisors sold out of Translate Bio, Inc. Common Stock (TBIO) in Q2 2021, closing a stake of 23,287 shares — an estimated $458K sold.

Citadel Advisors first reported a position in TBIO in Q1 2020 and held it in 5 quarters. The position peaked at $6.56M in Q2 2020. 145 funds tracked by Wall St. Rank hold TBIO as of Q2 2021.

Citadel Advisors reported no remaining Translate Bio, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Citadel Advisors sold 23,287 Translate Bio, Inc. Common Stock shares in Q2 2021, an estimated $458K.
Citadel Advisors first reported a position in Translate Bio, Inc. Common Stock in Q1 2020 and held it in 5 quarters.
Citadel Advisors's Translate Bio, Inc. Common Stock position peaked at $6.56M in Q2 2020.
145 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q2 2021.

Based on Citadel Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.